Ex­elix­is pulls a sur­prise win in thy­roid can­cer just days ahead of fi­nal Cabome­tyx read­out

Ex­elix­is added a thy­roid can­cer in­di­ca­tion to its su­per-sell­er Cabome­tyx’s la­bel on Fri­day — months be­fore the FDA was ex­pect­ed to make a de­ci­sion, and days …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER